Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2013

Open Access 01-12-2013 | Original investigation

Association between serum adipocyte fatty-acid binding protein concentrations, left ventricular function and myocardial perfusion abnormalities in patients with coronary artery disease

Authors: Chi-Lun Huang, Yen-Wen Wu, Chih-Cheng Wu, Lin Lin, Yu-Chin Wu, Pei-Ying Hsu, Yuh-Shiun Jong, Wei-Shiung Yang

Published in: Cardiovascular Diabetology | Issue 1/2013

Login to get access

Abstract

Background

Adipokines, including adipocyte fatty acid-binding protein (A-FABP), have been demonstrated to be involved in the pathogenesis of atherosclerosis. In the present study, we investigated the association of circulating A-FABP level with severity of myocardial perfusion abnormalities analyzed by Tl-201 dipyridamole single-photon emission computed tomography.

Methods

A total of 170 patients with coronary artery disease (CAD) from cardiovascular clinics were enrolled in the study. Serum A-FABP levels, echocardiography, and stress myocardial perfusion imaging results were analyzed.

Results

Compared with the patients with mild CAD (summed stress score [SSS] ≤ 8), those with moderate to severe CAD (SSS > 8) had significantly higher A-FABP concentrations. However, the difference was attenuated in the subgroup of patients with heart failure. In the correlation analyses, A-FABP level was correlated with age, body mass index, waist circumference, levels of creatinine, fasting glucose, high-sensitivity C-reactive protein, N-terminal pro-brain natriuretic peptide, adiponectin, and several echocardiographic parameters, including left ventricular ejection fraction. Multivariate logistic regression analysis demonstrated that the A-FABP level was not only associated with higher SSS (odds ratio, 1.30; 95% confidence interval [CI], 1.01–1.69; P = 0.048), but also an independent risk factor for heart failure (odds ratio 2.71, 95% CI, 1.23–5.94; P = 0.013).

Conclusions

Serum A-FABP levels not only were associated with myocardial perfusion abnormalities and left ventricular function, but also predicted the presence of heart failure in our patients with CAD.
Appendix
Available only for authorised users
Literature
1.
go back to reference Mamas MA, Deaton C, Rutter MK, Yuille M, Williams SG, Ray SG, New J, Gibson JM, Neyses L: Impaired glucose tolerance and insulin resistance in heart failure: underrecognized and undertreated?. J Card Fail. 2010, 16 (9): 761-768. 10.1016/j.cardfail.2010.05.027.CrossRefPubMed Mamas MA, Deaton C, Rutter MK, Yuille M, Williams SG, Ray SG, New J, Gibson JM, Neyses L: Impaired glucose tolerance and insulin resistance in heart failure: underrecognized and undertreated?. J Card Fail. 2010, 16 (9): 761-768. 10.1016/j.cardfail.2010.05.027.CrossRefPubMed
3.
go back to reference Baldasseroni S, Mannucci E, Orso F, Di Serio C, Pratesi A, Bartoli N, Marella GA, Colombi C, Foschini A, Valoti P, et al: Adiponectin in outpatients with coronary artery disease: independent predictors and relationship with heart failure. Nutr Metab Cardiovasc Dis. 2012, 22 (3): 292-299. 10.1016/j.numecd.2011.03.012.CrossRefPubMed Baldasseroni S, Mannucci E, Orso F, Di Serio C, Pratesi A, Bartoli N, Marella GA, Colombi C, Foschini A, Valoti P, et al: Adiponectin in outpatients with coronary artery disease: independent predictors and relationship with heart failure. Nutr Metab Cardiovasc Dis. 2012, 22 (3): 292-299. 10.1016/j.numecd.2011.03.012.CrossRefPubMed
4.
go back to reference Zhang MH, Na B, Schiller NB, Whooley MA: Association of resistin with heart failure and mortality in patients with stable coronary heart disease: data from the heart and soul study. J Card Fail. 2011, 17 (1): 24-30. 10.1016/j.cardfail.2010.08.007.CrossRefPubMed Zhang MH, Na B, Schiller NB, Whooley MA: Association of resistin with heart failure and mortality in patients with stable coronary heart disease: data from the heart and soul study. J Card Fail. 2011, 17 (1): 24-30. 10.1016/j.cardfail.2010.08.007.CrossRefPubMed
5.
go back to reference Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar N: Obesity and risk of incident heart failure in older men with and without pre-existing coronary heart disease: does leptin have a role?. J Am Coll Cardiol. 2011, 58 (18): 1870-1877. 10.1016/j.jacc.2011.06.057.CrossRefPubMed Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar N: Obesity and risk of incident heart failure in older men with and without pre-existing coronary heart disease: does leptin have a role?. J Am Coll Cardiol. 2011, 58 (18): 1870-1877. 10.1016/j.jacc.2011.06.057.CrossRefPubMed
6.
go back to reference Xu A, Wang Y, Xu JY, Stejskal D, Tam S, Zhang J, Wat NM, Wong WK, Lam KS: Adipocyte fatty acid binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem. 2006, 52 (3): 405-413. 10.1373/clinchem.2005.062463.CrossRefPubMed Xu A, Wang Y, Xu JY, Stejskal D, Tam S, Zhang J, Wat NM, Wong WK, Lam KS: Adipocyte fatty acid binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem. 2006, 52 (3): 405-413. 10.1373/clinchem.2005.062463.CrossRefPubMed
7.
go back to reference Makowski L, Brittingham KC, Reynolds JM, Suttles J, Hotamisligil GS: The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and IkappaB kinase activities. J Biol Chem. 2005, 280 (13): 12888-12895.PubMedCentralCrossRefPubMed Makowski L, Brittingham KC, Reynolds JM, Suttles J, Hotamisligil GS: The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and IkappaB kinase activities. J Biol Chem. 2005, 280 (13): 12888-12895.PubMedCentralCrossRefPubMed
8.
go back to reference Erbay E, Babaev VR, Mayers JR, Makowski L, Charles KN, Snitow ME, Fazio S, Wiest MM, Watkins SM, Linton MF, et al: Reducing endoplasmic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosis. Nat Med. 2009, 15 (12): 1383-1391. 10.1038/nm.2067.PubMedCentralCrossRefPubMed Erbay E, Babaev VR, Mayers JR, Makowski L, Charles KN, Snitow ME, Fazio S, Wiest MM, Watkins SM, Linton MF, et al: Reducing endoplasmic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosis. Nat Med. 2009, 15 (12): 1383-1391. 10.1038/nm.2067.PubMedCentralCrossRefPubMed
9.
go back to reference Lee MY, Li H, Xiao Y, Zhou Z, Xu A, Vanhoutte PM: Chronic administration of BMS309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells. Br J Pharmacol. 2011, 162 (7): 1564-1576. 10.1111/j.1476-5381.2010.01158.x.PubMedCentralCrossRefPubMed Lee MY, Li H, Xiao Y, Zhou Z, Xu A, Vanhoutte PM: Chronic administration of BMS309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells. Br J Pharmacol. 2011, 162 (7): 1564-1576. 10.1111/j.1476-5381.2010.01158.x.PubMedCentralCrossRefPubMed
10.
go back to reference Toruner F, Altinova AE, Akturk M, Kaya M, Arslan E, Bukan N, Kan E, Yetkin I, Arslan M: The relationship between adipocyte fatty acid binding protein-4, retinol binding protein-4 levels and early diabetic nephropathy in patients with type 2 diabetes. Diabetes Res Clin Pract. 2011, 91 (2): 203-207. 10.1016/j.diabres.2010.11.011.CrossRefPubMed Toruner F, Altinova AE, Akturk M, Kaya M, Arslan E, Bukan N, Kan E, Yetkin I, Arslan M: The relationship between adipocyte fatty acid binding protein-4, retinol binding protein-4 levels and early diabetic nephropathy in patients with type 2 diabetes. Diabetes Res Clin Pract. 2011, 91 (2): 203-207. 10.1016/j.diabres.2010.11.011.CrossRefPubMed
11.
go back to reference Kim YC, Cho YK, Lee WY, Kim HJ, Park JH, Park DI, Sohn CI, Jeon WK, Kim BI, Park SE, et al: Serum adipocyte-specific fatty acid-binding protein is associated with nonalcoholic fatty liver disease in apparently healthy subjects. J Nutr Biochem. 2011, 22 (3): 289-292. 10.1016/j.jnutbio.2010.02.007.CrossRefPubMed Kim YC, Cho YK, Lee WY, Kim HJ, Park JH, Park DI, Sohn CI, Jeon WK, Kim BI, Park SE, et al: Serum adipocyte-specific fatty acid-binding protein is associated with nonalcoholic fatty liver disease in apparently healthy subjects. J Nutr Biochem. 2011, 22 (3): 289-292. 10.1016/j.jnutbio.2010.02.007.CrossRefPubMed
12.
go back to reference Xu A, Vanhoutte PM: Adiponectin and adipocyte fatty acid binding protein in the pathogenesis of cardiovascular disease. Am J Physiol Heart Circ Physiol. 2012, 302 (6): H1231-H1240. 10.1152/ajpheart.00765.2011.CrossRefPubMed Xu A, Vanhoutte PM: Adiponectin and adipocyte fatty acid binding protein in the pathogenesis of cardiovascular disease. Am J Physiol Heart Circ Physiol. 2012, 302 (6): H1231-H1240. 10.1152/ajpheart.00765.2011.CrossRefPubMed
13.
go back to reference Xu A, Tso AW, Cheung BM, Wang Y, Wat NM, Fong CH, Yeung DC, Janus ED, Sham PC, Lam KS: Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation. 2007, 115 (12): 1537-1543. 10.1161/CIRCULATIONAHA.106.647503.CrossRefPubMed Xu A, Tso AW, Cheung BM, Wang Y, Wat NM, Fong CH, Yeung DC, Janus ED, Sham PC, Lam KS: Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation. 2007, 115 (12): 1537-1543. 10.1161/CIRCULATIONAHA.106.647503.CrossRefPubMed
14.
go back to reference von Eynatten M, Breitling LP, Roos M, Baumann M, Rothenbacher D, Brenner H: Circulating adipocyte fatty acid-binding protein levels and cardiovascular morbidity and mortality in patients with coronary heart disease: a 10-year prospective study. Arterioscler Thromb Vasc Biol. 2012, 32 (9): 2327-2335. 10.1161/ATVBAHA.112.248609.CrossRefPubMed von Eynatten M, Breitling LP, Roos M, Baumann M, Rothenbacher D, Brenner H: Circulating adipocyte fatty acid-binding protein levels and cardiovascular morbidity and mortality in patients with coronary heart disease: a 10-year prospective study. Arterioscler Thromb Vasc Biol. 2012, 32 (9): 2327-2335. 10.1161/ATVBAHA.112.248609.CrossRefPubMed
15.
go back to reference Doi M, Miyoshi T, Hirohata S, Nakamura K, Usui S, Takeda K, Iwamoto M, Kusachi S, Kusano K, Ito H: Association of increased plasma adipocyte fatty acid-binding protein with coronary artery disease in non-elderly men. Cardiovasc Diabetol. 2011, 10: 44-10.1186/1475-2840-10-44.PubMedCentralCrossRefPubMed Doi M, Miyoshi T, Hirohata S, Nakamura K, Usui S, Takeda K, Iwamoto M, Kusachi S, Kusano K, Ito H: Association of increased plasma adipocyte fatty acid-binding protein with coronary artery disease in non-elderly men. Cardiovasc Diabetol. 2011, 10: 44-10.1186/1475-2840-10-44.PubMedCentralCrossRefPubMed
16.
go back to reference Bao Y, Lu Z, Zhou M, Li H, Wang Y, Gao M, Wei M, Jia W: Serum levels of adipocyte fatty acid-binding protein are associated with the severity of coronary artery disease in Chinese women. PLoS One. 2011, 6 (4): e19115-10.1371/journal.pone.0019115.PubMedCentralCrossRefPubMed Bao Y, Lu Z, Zhou M, Li H, Wang Y, Gao M, Wei M, Jia W: Serum levels of adipocyte fatty acid-binding protein are associated with the severity of coronary artery disease in Chinese women. PLoS One. 2011, 6 (4): e19115-10.1371/journal.pone.0019115.PubMedCentralCrossRefPubMed
17.
go back to reference Wu YW, Yen RF, Chieng PU, Huang PJ: Tl-201 myocardial SPECT in differentiation of ischemic from nonischemic dilated cardiomyopathy in patients with left ventricular dysfunction. J Nucl Cardiol. 2003, 10 (4): 369-374. 10.1016/S1071-3581(03)00456-2.CrossRefPubMed Wu YW, Yen RF, Chieng PU, Huang PJ: Tl-201 myocardial SPECT in differentiation of ischemic from nonischemic dilated cardiomyopathy in patients with left ventricular dysfunction. J Nucl Cardiol. 2003, 10 (4): 369-374. 10.1016/S1071-3581(03)00456-2.CrossRefPubMed
18.
go back to reference Tilkemeier PL, Wackers FJ: Quality Assurance Committee of the American Society of Nuclear Cardiology: Myocardial perfusion planar imaging. J Nucl Cardiol. 2006, 13 (6): e91-e96. 10.1016/j.nuclcard.2006.08.012.CrossRefPubMed Tilkemeier PL, Wackers FJ: Quality Assurance Committee of the American Society of Nuclear Cardiology: Myocardial perfusion planar imaging. J Nucl Cardiol. 2006, 13 (6): e91-e96. 10.1016/j.nuclcard.2006.08.012.CrossRefPubMed
19.
go back to reference Bonow RO, Bennett S, Casey DE, Ganiats TG, Hlatky MA, Konstam MA, Lambrew CT, Normand SL, Piña IL, Radford MJ, et al: ACC/AHA clinical performance measures for adults with chronic heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures) endorsed by the Heart Failure Society of America. J Am Coll Cardiol. 2005, 46 (6): 1144-1178. 10.1016/j.jacc.2005.07.012.CrossRefPubMed Bonow RO, Bennett S, Casey DE, Ganiats TG, Hlatky MA, Konstam MA, Lambrew CT, Normand SL, Piña IL, Radford MJ, et al: ACC/AHA clinical performance measures for adults with chronic heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures) endorsed by the Heart Failure Society of America. J Am Coll Cardiol. 2005, 46 (6): 1144-1178. 10.1016/j.jacc.2005.07.012.CrossRefPubMed
20.
go back to reference Makowski L, Boord JB, Maeda K, Babaev VR, Uysal KT, Morgan MA, Parker RA, Suttles J, Fazio S, Hotamisligil GS, et al: Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med. 2001, 7 (6): 699-705. 10.1038/89076.PubMedCentralCrossRefPubMed Makowski L, Boord JB, Maeda K, Babaev VR, Uysal KT, Morgan MA, Parker RA, Suttles J, Fazio S, Hotamisligil GS, et al: Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med. 2001, 7 (6): 699-705. 10.1038/89076.PubMedCentralCrossRefPubMed
21.
go back to reference Furuhashi M, Tuncman G, Görgün CZ, Makowski L, Atsumi G, Vaillancourt E, Kono K, Babaev VR, Fazio S, Linton MF, et al: Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature. 2007, 447 (7147): 959-965. 10.1038/nature05844.PubMedCentralCrossRefPubMed Furuhashi M, Tuncman G, Görgün CZ, Makowski L, Atsumi G, Vaillancourt E, Kono K, Babaev VR, Fazio S, Linton MF, et al: Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature. 2007, 447 (7147): 959-965. 10.1038/nature05844.PubMedCentralCrossRefPubMed
22.
go back to reference Aragonès G, Saavedra P, Heras M, Cabré A, Girona J, Masana L: Fatty acid-binding protein 4 impairs the insulin-dependent nitric oxide pathway in vascular endothelial cells. Cardiovasc Diabetol. 2012, 11: 72-10.1186/1475-2840-11-72.PubMedCentralCrossRefPubMed Aragonès G, Saavedra P, Heras M, Cabré A, Girona J, Masana L: Fatty acid-binding protein 4 impairs the insulin-dependent nitric oxide pathway in vascular endothelial cells. Cardiovasc Diabetol. 2012, 11: 72-10.1186/1475-2840-11-72.PubMedCentralCrossRefPubMed
23.
go back to reference Holm S, Ueland T, Dahl TB, Michelsen AE, Skjelland M, Russell D, Nymo SH, Krohg-Sørensen K, Clausen OP, Atar D, et al: Fatty Acid binding protein 4 is associated with carotid atherosclerosis and outcome in patients with acute ischemic stroke. PLoS One. 2011, 6 (12): e28785-10.1371/journal.pone.0028785.PubMedCentralCrossRefPubMed Holm S, Ueland T, Dahl TB, Michelsen AE, Skjelland M, Russell D, Nymo SH, Krohg-Sørensen K, Clausen OP, Atar D, et al: Fatty Acid binding protein 4 is associated with carotid atherosclerosis and outcome in patients with acute ischemic stroke. PLoS One. 2011, 6 (12): e28785-10.1371/journal.pone.0028785.PubMedCentralCrossRefPubMed
24.
go back to reference Miyoshi T, Onoue G, Hirohata A, Hirohata S, Usui S, Hina K, Kawamura H, Doi M, Kusano KF, Kusachi S, et al: Serum adipocyte fatty acid-binding protein is independently associated with coronary atherosclerotic burden measured by intravascular ultrasound. Atherosclerosis. 2010, 211 (1): 164-169. 10.1016/j.atherosclerosis.2010.01.032.CrossRefPubMed Miyoshi T, Onoue G, Hirohata A, Hirohata S, Usui S, Hina K, Kawamura H, Doi M, Kusano KF, Kusachi S, et al: Serum adipocyte fatty acid-binding protein is independently associated with coronary atherosclerotic burden measured by intravascular ultrasound. Atherosclerosis. 2010, 211 (1): 164-169. 10.1016/j.atherosclerosis.2010.01.032.CrossRefPubMed
25.
go back to reference Furuhashi M, Ishimura S, Ota H, Hayashi M, Nishitani T, Tanaka M, Yoshida H, Shimamoto K, Hotamisligil GS, Miura T, et al: Serum fatty acid-binding protein 4 is a predictor of cardiovascular events in end-stage renal disease. PLoS One. 2011, 6 (11): e27356-10.1371/journal.pone.0027356.PubMedCentralCrossRefPubMed Furuhashi M, Ishimura S, Ota H, Hayashi M, Nishitani T, Tanaka M, Yoshida H, Shimamoto K, Hotamisligil GS, Miura T, et al: Serum fatty acid-binding protein 4 is a predictor of cardiovascular events in end-stage renal disease. PLoS One. 2011, 6 (11): e27356-10.1371/journal.pone.0027356.PubMedCentralCrossRefPubMed
26.
go back to reference Lee K, Santibanez-Koref M, Polvikoski T, Birchall D, Mendelow AD, Keavney B: Increased expression of fatty acid binding protein 4 and leptin in resident macrophages characterizes atherosclerotic plaque rupture. Atherosclerosis. 2013, 226 (1): 74-81. 10.1016/j.atherosclerosis.2012.09.037.PubMedCentralCrossRefPubMed Lee K, Santibanez-Koref M, Polvikoski T, Birchall D, Mendelow AD, Keavney B: Increased expression of fatty acid binding protein 4 and leptin in resident macrophages characterizes atherosclerotic plaque rupture. Atherosclerosis. 2013, 226 (1): 74-81. 10.1016/j.atherosclerosis.2012.09.037.PubMedCentralCrossRefPubMed
27.
go back to reference Miyoshi T, Doi M, Hirohata S, Kamikawa S, Usui S, Ogawa H, Sakane K, Izumi R, Ninomiya Y, Kusachi S: Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients. Heart Vessels. 2011, 26 (4): 408-413. 10.1007/s00380-010-0060-x.CrossRefPubMed Miyoshi T, Doi M, Hirohata S, Kamikawa S, Usui S, Ogawa H, Sakane K, Izumi R, Ninomiya Y, Kusachi S: Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients. Heart Vessels. 2011, 26 (4): 408-413. 10.1007/s00380-010-0060-x.CrossRefPubMed
28.
go back to reference Wu YW, Kao HL, Huang CL, Chen MF, Lin LY, Wang YC, Lin YH, Lin HJ, Tzen KY, Yen RF, et al: The effects of 3-month atorvastatin therapy on arterial inflammation, calcification, abdominal adipose tissue and circulating biomarkers. Eur J Nucl Med Mol Imaging. 2012, 39 (3): 399-407. 10.1007/s00259-011-1994-7.CrossRefPubMed Wu YW, Kao HL, Huang CL, Chen MF, Lin LY, Wang YC, Lin YH, Lin HJ, Tzen KY, Yen RF, et al: The effects of 3-month atorvastatin therapy on arterial inflammation, calcification, abdominal adipose tissue and circulating biomarkers. Eur J Nucl Med Mol Imaging. 2012, 39 (3): 399-407. 10.1007/s00259-011-1994-7.CrossRefPubMed
29.
go back to reference Liu M, Zhou M, Bao Y, Xu Z, Li H, Zhang H, Zhu W, Zhang J, Xu A, Wei M, et al: Circulating adipocyte fatty acid-binding protein levels are independently associated with heart failure. Clin Sci (Lond). 2013, 124 (2): 115-122. 10.1042/CS20120004.CrossRef Liu M, Zhou M, Bao Y, Xu Z, Li H, Zhang H, Zhu W, Zhang J, Xu A, Wei M, et al: Circulating adipocyte fatty acid-binding protein levels are independently associated with heart failure. Clin Sci (Lond). 2013, 124 (2): 115-122. 10.1042/CS20120004.CrossRef
30.
go back to reference Djoussé L, Bartz TM, Ix JH, Kochar J, Kizer JR, Gottdiener JS, Tracy RP, Mozaffarian D, Siscovick DS, Mukamal KJ, et al: Fatty acid-binding protein 4 and incident heart failure: the Cardiovascular Health Study. Eur J Heart Fail. 2013, 15 (4): 394-399. 10.1093/eurjhf/hfs196.PubMedCentralCrossRefPubMed Djoussé L, Bartz TM, Ix JH, Kochar J, Kizer JR, Gottdiener JS, Tracy RP, Mozaffarian D, Siscovick DS, Mukamal KJ, et al: Fatty acid-binding protein 4 and incident heart failure: the Cardiovascular Health Study. Eur J Heart Fail. 2013, 15 (4): 394-399. 10.1093/eurjhf/hfs196.PubMedCentralCrossRefPubMed
31.
go back to reference Levine B, Kalman J, Mayer L, Fillit HM, Packer MP: Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990, 323 (4): 236-241. 10.1056/NEJM199007263230405.CrossRefPubMed Levine B, Kalman J, Mayer L, Fillit HM, Packer MP: Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990, 323 (4): 236-241. 10.1056/NEJM199007263230405.CrossRefPubMed
32.
go back to reference Witteles RM, Fowler MB: Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J Am Coll Cardiol. 2008, 51 (2): 93-102. 10.1016/j.jacc.2007.10.021.CrossRefPubMed Witteles RM, Fowler MB: Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J Am Coll Cardiol. 2008, 51 (2): 93-102. 10.1016/j.jacc.2007.10.021.CrossRefPubMed
33.
go back to reference Lamounier-Zepter V, Look C, Alvarez J, Christ T, Ravens U, Schunck WH, Ehrhart-Bornstein M, Bornstein SR, Morano I, et al: Adipocyte fatty acid-binding protein suppresses cardiomyocyte contraction: a new link between obesity and heart disease. Circ Res. 2009, 105 (4): 326-334. 10.1161/CIRCRESAHA.109.200501.CrossRefPubMed Lamounier-Zepter V, Look C, Alvarez J, Christ T, Ravens U, Schunck WH, Ehrhart-Bornstein M, Bornstein SR, Morano I, et al: Adipocyte fatty acid-binding protein suppresses cardiomyocyte contraction: a new link between obesity and heart disease. Circ Res. 2009, 105 (4): 326-334. 10.1161/CIRCRESAHA.109.200501.CrossRefPubMed
34.
go back to reference Iwamoto M, Miyoshi T, Doi M, Takeda K, Kajiya M, Nosaka K, Nakayama R, Hirohata S, Usui S, Kusachi S, et al: Elevated serum adipocyte fatty acid-binding protein concentrations are independently associated with renal dysfunction in patients with stable angina pectoris. Cardiovasc Diabetol. 2012, 11: 26-10.1186/1475-2840-11-26.PubMedCentralCrossRefPubMed Iwamoto M, Miyoshi T, Doi M, Takeda K, Kajiya M, Nosaka K, Nakayama R, Hirohata S, Usui S, Kusachi S, et al: Elevated serum adipocyte fatty acid-binding protein concentrations are independently associated with renal dysfunction in patients with stable angina pectoris. Cardiovasc Diabetol. 2012, 11: 26-10.1186/1475-2840-11-26.PubMedCentralCrossRefPubMed
Metadata
Title
Association between serum adipocyte fatty-acid binding protein concentrations, left ventricular function and myocardial perfusion abnormalities in patients with coronary artery disease
Authors
Chi-Lun Huang
Yen-Wen Wu
Chih-Cheng Wu
Lin Lin
Yu-Chin Wu
Pei-Ying Hsu
Yuh-Shiun Jong
Wei-Shiung Yang
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2013
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-12-105

Other articles of this Issue 1/2013

Cardiovascular Diabetology 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine